Objective: To evaluate the prevalence of human herpesviruses (HHV) 1-6 and community-acquired respiratory viruses (CARVs) in specimens from patients with nasal polyposis undergoing functional endoscopic sinus surgery (FESS) and investigate the potential clinical role. Methods: Viral occurrence was evaluated by molecular methods in polyp, turbinate mucosa, and pre- and postoperative scraping specimens from 35 consecutive patients at different time points in relation to FESS. Results: Overall, 21 patients (60%) were positive to at least one virus in at least one specimen; in particular, 12.1% of all specimens for HHV-6 (3/35 polyps, 11/31 turbinates, 1 presurgical scraping) and 10.5% for Epstein-Barr virus (EBV) (8/35 polyps, 3/31 turbinates, 1/29 pre- and 1/29 postsurgical scraping), followed by CMV and HSV-1 (both 1.6%; 1/35 polyps, 1/29 postsurgical scraping and 2/35 polyps, respectively). EBV positivity tended to be higher in polyps, as well as HHV-6 in adjacent healthy turbinate mucosa, although no significant association was found. Only one preoperative cytological specimen was positive to parainfluenza virus-1. Conclusion: No association between the development of nasal polyps, herpesviruses and CARVs seems to exist. However, the higher EBV frequency in polyps could suggest a causative role or persistence in the inflammatory lymphoid tissue.

Keywords:
Cytomegalovirus, Epstein-Barr virus, Human herpesvirus 6, Community-acquired respiratory viruses, Nasal polyposis, Functional endoscopic sinus surgery
1.
Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, Cohen N, Cervin A, Douglas R, Gevaert P, Georgalas C, Goossens H, Harvey R, Hellings P, Hopkins C, Jones N, Joos G, Kalogiera L, Kern B, Kowalski M, Price D, Riechelmann H, Schlosser R, Senior B, Thomas M, Toskala E, Voegels R, Wang DY, Wormald PJ: European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinology 2012;23(suppl):1-298.
2.
Badia L, Lund V: Topical corticosteroids in nasal polyposis. Drugs 2001;61:573-578.
3.
Yamada T, Fujieda S, Mori S, Yamamoto H, Saito H: Macrolide treatment decreased the size of nasal polyps and IL-8 levels in nasal lavage. Am J Rhinol 2000;14:143-148.
4.
Stammberger H: Endoscopic endonasal surgery - new concepts and treatment of recurring rhinosinusitis: I. Anatomic and pathophysiologic considerations; II. Surgical considerations. Otolaryngol Head Neck Surg 1986;94:143-156.
5.
Zaravinos A, Bizakis J, Soufla G, Sourvinos G, Spandidos DA: Mutations and differential of the ras family genes in human nasal polyposis. Int J Oncol 2007;31:1051-1059.
6.
Watelet JB, Claeys C, Perez-Novo C, Gevaert P. Van Cauwenberge P, Bachert C: Transforming growth factor-β1 in nasal remodeling: differences between chronic rhinosinusitis and nasal polyposis. Am J Rhinol 2004;18:267-272.
7.
Zaravinos A, Soufla G, Bizakis J, Spandidos DA: Expression analysis of VEGFA, FGF2, TGF-β1, EGF and IGF-1 in human nasal polyposis. Oncol Rep 2008;19:385-391.
8.
Hamilos DL, Leung DY, Wood R, Meyers A, Stephens JK, Barkans J, Meng Q, Cunningham L, Bean DK, Kay AB, Hamid Q: Chronic hyperplastic sinusitis: association of tissue eosinophilia with mRNA expression of granulocyte-macrophage colony-stimulating factor and interleukin-3. J Allergy Clin Immunol 1993;92:39-48.
9.
Mygind N: Nasal polyposis. J Allergy Clin Immunol 1990;86:827-829.
10.
Klemens JJ, Thomson K, Longerman A, Naclerio RM: Persistent inflammation and hyperresponsiveness following viral rhinosinusitis. Laryngoscope 2006;116:1236-1240.
11.
Stierna P, Carlsoo B: Histopathological observations in chronic maxillary sinusitis. Acta Otolaryngol (Stockh) 1996;116:316-321.
12.
Hoffmann M, Klose N, Gottschlich S, Görögh T, Fazel A, Rittgen W, Ambrosch P, Schwarz E, Kahn T: Detection of human papillomavirus DNA in benign and malignant sinonasal neoplasms. Cancer Lett 2006;239:64-70.
13.
Zhou Y, Hu M, Liu C: Human papillomavirus DNA test in nasal polyposis. Lin Chuang Er Bi Yan Hou Ke Za Zhi 2001;15:212-213.
14.
Hoffmann M, Kahn T, Goeroegh T, Lohrey C, Gottshlich S, Meyer J, Rudert H, Maune S: Tracing human papillomavirus DNA in nasal polyps by polymerase chain reaction. Acta Otolaryngol 2000;120:872-875.
15.
Lund VJ, Mackay IS: Staging in rhinosinusitis. Rhinology 1993;31:183-184.
16.
Cheung WWY, Chan AC, Loke SL, Srivastava G, Pittaluga S, Lim LY, Ho FCS: Latent sites of Epstein-Barr virus infection. Am J Clin Pathol 1993;100:502-506.
17.
Tao Q, Srivastava G, Chan ACL, Chung LP, Loke SL, Ho FCS: Evidence for lytic infection of Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. J Med Virol 1995;45:71-77.
18.
Tao Q, Srivastava G, Dickens P, Ho FCS: Detection of Epstein-Barr virus-infected mucosal lymphocytes in nasal polyps. Am J Pathol 1996;149:1111-1118.
19.
Zaravinos A, Bizakis J, Spandidos DA: Prevalence of human papilloma virus and human herpes virus types 1-7 in human nasal polyps. J Med Virol 2009;81:1613-1619.
20.
Sham CL, To KF, Chan PK, Lee DL, Tong MC, van Hasselt CA: Prevalence of human papilloma virus, Epstein-Barr virus, p21, and p53 expression in sinonasal inverted papilloma, nasal polyp, and hypertrophied turbinate in Hong Kong patients. Head Neck 2012;34:520-533.
21.
Wood AJ, Antoszewska H, Fraser J, Douglas RG: Is chronic rhinosinusitis caused by persistent respiratory virus infection? Int Forum Allergy Rhinol 2011;1:95-100.
22.
Jang YJ, Kwon HJ, Park HW, Lee BJ: Detection of rhinovirus in turbinate epithelial cells of chronic sinusitis. Am J Rhinol 2006;20:634-636.
23.
Falcone V, Ridder GJ, Panning M, Bierbaum S, Neumann-Haefelin D, Huzly D: Human bocavirus DNA in paranasal sinus mucosa. Emerg Infect Dis 2011;17:1564-1565.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.